Fifty women with breast cancer metastatic to bone or bone marrow involvement on light microscopy at the time of initial evaluation were treated with high-dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) transplantation with CD34
breast cancer.
1,2 A recent phase III study of HDC vs continued standard-dose CMF did not find a benefit in patients in CR, 3 although patients were treated with a different highdose chemotherapy regimen.
Because of concerns relating to the possibility of reinfusing tumor cells, many initial studies excluded patients who were found to have bone marrow positive for breast cancer cells by routine histology. More sensitive methods such as immunohistochemistry and PCR have lowered the threshold for tumor cell detection such that contaminating cancer cells are commonly detectable even in patients with microscopically negative bone marrow. 4, 5 Peripheral blood progenitor cells have rapidly replaced bone marrow as the hematopoietic progenitor source of choice. 6, 7 Although the frequency of tumor cells in these PBPC collections appears reduced, a number of studies have found tumor cells in such collections. 4, 8, 9 In bone marrow transplantation for high-risk primary breast cancer, the presence of tumor cells in the bone marrow product has been associated with shorter diseasefree and overall survivals. 10 
CD34
+ cells from bone marrow and peripheral blood progenitor cells include the progenitor cells necessary for reconstitution of hematopoiesis after HDC. [11] [12] [13] [14] Since the majority of breast cancers do not express CD34, positive selection of CD34 + cells provides a method for depletion of tumor cells without compromising the ability of PBPC to reconstitute normal hematopoiesis.
PBPC are cryopreserved after collection and stored during the preparative chemotherapy regimen before reinfusion. To protect the cells from injury during the cryopreservation procedure, a number of methods have been developed. One of the most common methods is freezing the cells in dimethylsulfoxide (DMSO) with autologous plasma. DMSO in the PBPC product can cause a number of side-effects when reinfused to the patient. Reactions may range from mild nausea, vomiting and diarrhea, to more serious, including bronchospasm, bradycardia and, rarely, cardiac arrest. 15 Selection of CD34 + cells decreases the volume of the PBPC product and the amount of DMSO that is infused to the patients. Such selection may therefore reduce the side-effect profile of the PBPC product. CD34 + selection results in an essentially lymphoiddeplete graft. 16 Because of this, there is concern regarding the increased risk of opportunistic infections. The current phase II investigation was conducted to evaluate the safety of CD34-selected transplant. At the same time as treatment, the toxicity profile of the PBPC infusion and therapeutic outcomes were evaluated as well as the possible infectionrelated complications of this transplantation strategy.
Patients and methods

Patient group
Fifty patients, 22-60 years of age, with metastatic breast cancer who were bone marrow positive for breast cancer cells by routine light microscopy or had multiple skeletal metastasis were eligible for this study. Patients were required to have a SWOG performance status of 0 or 1, and adequate organ function. This included a left ventricular ejection of Ͼ50%, DLCO Ͼ60%, no evidence of hepatic dysfunction, and a creatinine clearance of Ͼ50 ml/min. Patients with CNS metastasis were excluded. All patients had bilateral bone marrow aspirations and biopsies evaluated for routine light microscopic evidence of metastatic disease.
All women received four cycles of induction chemotherapy. They received doxorubicin 60 mg/m 2 and paclitaxel at 175 mg/m 2 if they had not received prior anthracyclines and vinorelbine 25 mg/m 2 and docetaxel 75 mg/m 2 if they had.
PBPC mobilization and collection
PBPC were mobilized with cyclophosphamide 2 g/m 2 and paclitaxel 170 mg/m 2 followed by filgrastim 10 g/kg.
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The first day, paclitaxel was diluted in 500 ml D5W in a glass container with a polyethylene-lined tubing and a 0.22 m in-line filter and infused intravenously over 24 h. Patients were pre-medicated with dexamethasone 20 mg orally 12 and 6 h before paclitaxel and dexamethasone 20 mg i.v., diphenhydramine 50 mg i.v. and cimetidine 300 mg i.v. 20 min before paclitaxel administration. Cyclophosphamide 2.0 g/m 2 was given intravenously 1 h after completion of the paclitaxel.
Cyclophosphamide was infused over 1 h. All patients received Mesna for the prevention of hemorrhagic cystitis. The Mesna dose was 2.0 g/m 2 in divided doses prior to administration of cyclophosphamide 4 and 8 h after. Twenty-four hours following chemotherapy, patients received filgrastim 10 g/kg/day subcutaneously. Patients also received ciprofloxacin, 500 mg three times a day as bacterial prophylaxis.
Apheresis was started when the peripheral white blood count exceeded 2.0 × 10 9 /l and у20 CD34 + cells/l were detected in the peripheral blood. An unmanipulated apheresis product containing у1.5 × 10 6 CD34 + cell/kg was cryopreserved as a backup in the event of non-engraftment.
CD34
+ cell purification
Positive selection of the PBPC product was performed according to the standard Isolex 300i protocol, which is briefly described as follows: the PBPC product is incubated with human intravenous immunoglobulin and calciummagnesium-free PBS. An automated platelet wash is performed on the apheresis product prior to the sensitization and isolation steps. Sensitization is performed by incubating the cells for 15 min with 2.5 mg of anti-CD34 antibody, after which the cells are washed to remove excess/unbound antibody.
Freshly prepared sheep-anti-mouse paramagnetic microspheres (Dynal, Great Neck, NY, USA) are then added to the washed, sensitized cells in the automated procedure. The bead/target cell complexes are retained in the separation chamber, and the non-target cells are washed away. Using the Stem Cell Releasing Agent (Nexell Therapeutics, Irvine, CA, USA), the CD34 + cells are displaced from the anti-CD34 antibody, selectively releasing them from the beads. This requires a 30-min incubation at room temperature, after which the target cells are washed and collected. The CD34
+ product was cryopreserved in a final concentration of 10% DMSO in a volume of 50 ml. The cells were stored at −196°C using controlled rate freezing. On the day of reinfusion, bags are thawed by immersion in a water bath at 37°C. The thawed product is then directly infused without washing.
Enumeration of CD34
+ cells
Aliquots of the peripheral blood before apheresis, the apheresis product and the CD34-enriched fraction were evaluated for CD34 + cells. Erythrocytes were lysed with ammonium chloride. The aliquots were then incubated with phycoerthyrin-conjugated anti-CD34 (HPCA-2; Becton Dickinson, Mountain View, CA, USA) and FTIC-conjugated CD45. After incubation and washing, the samples were analyzed on a FACScan (Becton Dickinson) and 75 000 events acquired. A gating strategy of CD45 staining vs side-angle light-scattered properties was used as the primary gate according to ISHAGE guidelines. 18 
Immunohistochemistry assay
Control and patient cell suspensions were diluted to 1 × 10 6 cells/ml and centrifuged on to glass microscope slides in a Hettich Universal 16 Cytocentrifuge. Slides were air-dried and fixed for 20 min in 1% Paraformaldehyde/Triton-X solution. Cells were blocked for non-specific binding with Super Block (Scytek No. AAA500). Primary mouse monoclonal antibodies (Sigma C2562; Sigma-Aldrich, St Louis, MO, USA) specific for cytokeratins 1, 4, 5, 6, 8, 10, 13, 18, and 19 were applied at a dilution of 1:100. Biotinylated anti-mouse IgG (DAKO Z0259) was applied as a secondary Ab, followed by APAAP (Sigma A7827), and avidinbiotin-horseradish-peroxidase complex (Vectastain SK-5100; Vector Laboratories, Burlingame, CA, USA). Counterstaining was performed with Mayer's hematoxylin. Slides were directly scanned by light microscopy.
High-dose chemotherapy
The chemotherapy used was STAMP I (cyclophosphamide 1875 mg/m 2 i.v. on days 1, 2 and 3, cisplatin 55 mg/m 2 /day by continuous i.v. infusion days 1, 2 and 3, and carmustine 600 mg/m 2 i.v. on day 4). Details of the drug administration have been reported in previous manuscripts. 19 Two days after the completion of the HDC, the cryopreserved CD34-selected PBPC were infused. CD34-selected PBPC were thawed at the bedside in a 37°C water bath and administered via a central venous catheter without washing.
Clinical care
On the day of stem cell reinfusion, patients were discharged to the on-site residential facility and were followed daily in the outpatient transplant clinic where they received hematologic, electrolyte, antimicrobial and fluid support. Patients received transfusions to obtain a hematocrit of 42% before admission for high-dose chemotherapy. Following chemotherapy, the hematocrit was maintained at 36% until neutrophil recovery. Patients also received single-donor platelet transfusions for platelet count of less than 25 000/l until neutrophil engraftment. All blood products were leukoreduced and irradiated. Patients received filgrastim 5 g/kg daily until the ANC was greater than 5.0 × 10 9 /l for 3 consecutive days. All patients received prophylactic antibiotic (rifampim and ciprofloxacin). In the event of fever higher than 38.5°C, blood cultures were obtained, and antibiotic therapy was changed to vancomycin 30 mg/kg and tobramycin 5 mg/kg given as a single daily dose. No anti-viral or anti-fungal prophylaxis was given.
The diagnosis of pulmonary toxicity was made on clinical grounds. The following parameters were useful in making the diagnosis: a drop in the DLCO (diffusing capacity) of у25%; increased shortness of breath on exertion; unexplained fevers; non-productive cough; abnormal chest Xrays; a drop in the oxygen saturation of at least 6% during exercise. Routine PFTs were performed every 6 weeks and whenever clinically indicated.
Data analysis
The probabilities of disease-free survival (DFS) and overall survival (OS) were calculated using the method of Kaplan and Meier.
Results
Patient characteristics
Characteristics of the 50 patients are listed in Table 1 . The median age was 46 years (range 22-60 years). The median time from diagnosis of breast cancer to the transplant was 29.1 months (range 2.1-155.4 months). The median time from diagnosis of metastatic disease to transplant was 9.5 months (range 2.2-119 months). Forty-one percent had had prior adjuvant chemotherapy. Thirty-eight percent had received prior chemotherapy for metastatic disease (range 0-2 prior regimens). Forty-one percent of the women had received prior adjuvant hormonal therapy, and 24% had undergone hormonal therapy for metastatic disease. Twenty-nine percent had received prior adjuvant radiation 
Mobilization and collection of PBPC
All patients mobilized an adequate number of CD34 + PBPC for both selection and a back-up product. Because of a previous allergic reaction to paclitaxel, two patients received only cyclophosphamide at 4 g/m 2 for PBPC mobilization.
Progenitor cell purity and recovery
Seventy-one CD34 selection procedures were performed on the 50 patients undergoing PBPC transplantation. One to three selection procedures were performed on each patient. All selection procedures were performed utilizing the Isolex 300I (Nexell Therapeutics). The summary data pertaining to the pheresis and selection products are summarized in Table 2 . The median purity of the CD34 
Immunohistochemistry
Immunohistochemistry was performed on the unprocessed back-up product and CD34
+ fraction in 41 patients. In nine patients, the analysis was not performed. IHC-positive cells were detected in 18 of the backup products with between two and 174 IHC-positive/10 6 nucleated cells. Only one sample following CD34 selection showed any detected IHC-positive cells. None of the patients with IHC-negative productive backup had detectable IHC-positive in the selected product.
Hematological recovery
Fifty patients have received their selected CD34 + PBPC after high-dose chemotherapy. The median time to recovery of neutrophils more than 0.5 × 10 9 /l was 9 days (range 9-14 days) ( Table 1 ). The time to ANC greater than 500/l was not affected by the number of CD34 + cells infused. The median time to platelet transfusion independence (Ͼ25 000/l) was 11 days (range 4-30 days). No patient required a backup progenitor cell product.
Clinical course
All patients tolerated the infusion of CD34-selected PBPC without any significant adverse events during or following the cell infusion. Patients receiving the selected PBPC routinely received less volume of PBPC product (median of 98 ml (range 89-285 ml)) and consequently less DSMO than comparable patients receiving unselected PBPC transplants. No patients experienced nausea, bradycardia or respiratory distress with the stem cell infusions. These are common accompaniments of the larger volume cryopreserved regular stem cell infusions. None of the patients died before engraftment and therefore all patients were evaluable for engraftment.
Two patients developed fever during the neutropenic phase and were started on empiric treatment with a single daily dose of vancomycin and tobramycin. No patients developed documented bacteremia, and the fever resolved with hematopoietic recovery. One patient required readmission for fever after the initial discharge.
Post-transplant toxicity
Seventy-five percent of the women developed pulmonary toxicity requiring steroid therapy with a median duration of 10 weeks. A 20% decline in median DLCO was documented at 12 months of follow-up from an initial median DLCO of 79% (range 50-120%) to a median posttransplant DLCO at 12 months of 59% (range 57-62). Four women started steroid therapy in the first month post transplant, and all were off steroids by 8 months post transplant. The median time to start steroid therapy was 1 month (range 0-3 months). Patients received prophylactic sulfamathoxazole/trimethoprim while on steroid therapy.
Treatment-related mortality was 4.0%. One woman died of multi-organ failure at 3.5 weeks. She had had significant liver involvement prior to transplant, and early liver failure post transplant. She also developed CMV pneumonitis. At autopsy, she had no evidence of breast cancer. A second died at 4.4 months of thrombotic thrombocytopenic purpura.
Post-transplant infectious diseases
Opportunistic infections developed in 47% of patients, the most common being herpes zoster and herpes simplex virus (Table 3) . Two patients developed CMV at 0.75 and 2 months post transplant. They expired at 0.75 and 6 months, respectively, post transplant. Two patients developed Pneumocystis carinii pneumonia (PCP) at 8 and 9 months post transplant. Both developed this complication while receiving steroids during post-transplant chemotherapy for recurrent disease. Neither was receiving PCP prophylaxis at the time of infection. Both died of this complication.
Four patients developed invasive fungal infections. Two developed and died from invasive Aspergillus fumigates at 6 and 9 months post transplant. One patient developed Candidal liver abscesses day 55 post transplant. This patient died of progressive liver disease at 8 months post transplant. A second had Candida albicans of the lung at autopsy. Diabetes mellitus seemed to contribute to the development of CMV and fungal disease. Diabetes mellitus was a pre-existing diagnosis in three patients. One had CMV at 3.5 weeks, one had Candidal liver abscesses at 55 days, and a third died of invasive aspergillosis. Steroid therapy was not associated with an overall increase in the incidence of opportunistic infections. Four of the 10 women who developed herpes zoster never received steroids. One of the two who developed cytomegalovirus never received steroids. One of the two who developed invasive Candidiasis never received steroids. Both women who developed aspergillus were on steroids and both died with this infection.
Survival
Because all women had to have either bone or bone marrow involvement, the best response recorded was frequently 'stable disease' for those with bone disease. Seventy-one percent had stable disease as their best response. Twentytwo percent had a complete remission in soft tissue. Median progression-free survival was 11.6 months. The PFS was 17.9% (95% CI, 0.4-31.8) at 39.6 months. At 1 year, the overall and progression-free survival rates were 62.5% (95% CI, 48.8-76.2) and 44.3% (95% CI, 29.9-59%). Median overall survival was 26 months. At a follow-up of 40 months, 23.7% (95% CI, 0.4-43.9) of the patients are alive at 34.6 months following transplant. The progression- Table 3 Infectious complications
Infection Incidence Median onset post ASCT
Varicella zoster 22.5% 5.4 months 7.5% post-herpetic (range 1.6-10 months) neuralgia Herpes simplex 12.5% 8 days (range 1 day to 4 months) Cytomegalovirus 5% (n = 2); 0.75 and 2 months gastrointestinal tract and lung Pneumocystis carinii 5% (n = 2) 8 and 9 months pneumonia Invasive aspergillus 5% (n = 2); lung 6 and 9 months Invasive Candidiasis 5% (n = 2); liver 1.8 and 6 months abscesses and lung 
Discussion
Tumor cells in the bone marrow are found in a number of patients with high-risk primary breast cancer and a majority of women with metastatic breast cancer if sensitive methods such as immunohistochemistry or PCR are used. [20] [21] [22] [23] In patients undergoing HDC and autologous bone marrow transplants, the presence of IHC-positive cells in the bone marrow after three cycles of CAF chemotherapy has been associated with worse disease-free and overall survivals. 21 Whether the presence of tumor cells in the bone marrow is a predictor of resistance of the tumor, or reinfusion of the tumor cells contributes to the relapse is not known.
Our study did not evaluate the effect of CD34 selection on relapse and overall survival compared to unselected PBPC products. Other studies have looked at this in small groups of patients who received either CD34-selected PBPC or unmodified PBPC transplants. 24, 25 In the study of Ahmed et al, 24 15 patients received CD34-selected stem cells and 30 patients received unmanipulated stem cells for stage IV breast cancer. They found no difference in the median overall and progression-free survivals. The major site of relapse was the previous site of disease exclusively in 7/15 in the CD34-selected group and 18/30 in the unmanipulated patients. Relapse in additional sites was found in 3/15 in selected and 11/30 in the unmanipulated group. Only four patients in that study had bone disease. Yanovich and coworkers 25 randomized women with either stage II, III or IV breast cancer to either CD34-selected or unmanipulated PBPC following HDC. Twenty-four patients with stage IV disease were randomized to CD34 selection and 18 to an unfractionated cell group. No difference in the overall or DFS between the two groups was observed, but clearly this analysis was underpowered. The number of patients with bone or bone marrow disease was not reported in this study. In a recently communicated study, patients with breast cancer metastatic to bone were randomized after four cycles of doxorubicin, 5-fluorouracil and methotrexate (AFM) to receive either a transplant using the same HDC as in the current study or to observation. In both groups, the progression-free survival averaged 13 months. However, while all observation patients had progressed by 2 years of follow-up, approximately 20% of those receiving HDC were without disease progression with close to 5 years of follow-up. The median survival in the transplant group was approximately 19 months; in the 3-year group, survival was 40%. 26 Improved survival occurred with highdose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer and only bone metastases treated with induction adriamycin AFM. The outcomes obtained in the current study with HDC are consistent with the results obtained in this randomized study of bone predominant metastases.
One concern in PBPC modification by CD34 selection is potential delay in hematopoietic recovery. A number of randomized studies comparing the hematopoietic recovery in CD34-selected vs non-selected autologous transplant found no significant delay in recovery of neutrophils or platelets in the CD34-selected recipients. 12, 24, 25 Our study found a median ANC recovery time of 9 days, with median time to platelet transfusion independence of 12 days, which is in agreement with previous trials. The use of the CD34-selected PBPC did not have any deleterious effect on the outpatient transplant approach in our study. The rate of readmission was not increased compared to what we find with unmodified PBPC transplants.
The effects on immunological recovery following CD34-selected autologous transplants have been of concern. Some have shown delayed recovery of the lymphoid and myeloid lines. In T cell-depleted allogeneic transplants, the CD4/CD8 ratio is low for the first 6 months post transplant and then starts to recover, reaching normal levels by 13-18 months. 27 Functional capacity of the lymphocytes was not normal in the T cell-deplete graft until 12 months. 27 Immune recovery in an autologous transplant setting is quite different from an allogeneic setting because of the lack of immunosuppressive drugs and the lack of GVHD. Previously, we have found a prompt recovery of antigenpresenting CD11c
+ dendritic cells and normal levels of NK cells, T cells and B cells, but an abnormal composition of the T cell populations following CD34 + -selected autologous transplants. 28 We found that the patients had a marked and significant reduction in CD4 + CD8 − TCR ␣␤ + similar to that previously reported. 12, 29 We also found a reduction in naive CD8
+ T cells (CD8
. This immune impairment may or may not translate into an increase in infection rate. In a phase III trial of CD34 selection in multiple myeloma, there was no difference in the incidence of infection during the transplant period (day 0 to 100) or post-transplant (after day 100) periods. 12 Rates of CMV antigenemia and CMV infections have been reported to be as high as 39-45% and 2-10%, respectively, in the autologous setting. 30, 31 A previous report of CD34-selected PBPC transplants found that seven of 31 (22.6%) of the CD34-selected patients developed CMV disease compared to 10 or 237 (4.2%) of those receiving unselected transplants. 32 We found two patients with CMV disease, although patients were not routinely evaluated for CMV pp65 antigemia or shell vial culture positivity.
Reactivation of herpes zoster can also be a significant problem following transplantation. Patients have the same risk of varicella zoster infections regardless of type of transplant. Twenty-three to 32% have been reported in the autologous setting, and 17-52% have been reported in the allogeneic setting. 33, 34 Our report of 22.5% does not indicate that CD34 selection had an effect on this infection.
The highest risk for invasive fungal infections for the autologous transplant candidates is during the immediate post-transplant neutropenic period. In a study of 250 patients, none of those receiving an autologous transplant developed invasive aspergillus after recovering from neutropenia. 35 In our study, both patients developed this problem well outside this period, at 6 and 9 months. The incidence of invasive Candidal infections in the autologous setting is unknown, but one study reported that 90% of these infections were in the allogeneic setting with an overall rate of 11.4%, suggesting an autologous rate of approximately 1%. In our study, two patients, or 5%, developed the problem. This is likely within normal variation, and does not suggest an increase in this CD34-selected population. The major cause of mortality following HDC and autologous transplant for both high-risk primary and metastatic breast cancer is still disease recurrence. Patients with metastatic breast cancer have a higher tumor burden, and CD34 selection may or may not have a significant effect until more effective regimens are developed. The randomized study comparing CD34-selected and non-selected autografts in stage II to IV breast cancer has had very short follow-up. At 1 year, no difference was found between the two arms; however, considering the small number of patients in disparate prognostic groups, a statistical difference may not be expected even with longer follow-up. 25 The 22% progression-free survival at 3 years reported in this study is a hopeful statistic. The disparate reports of progression-free survival in the high-dose setting make it impossible to assign importance to CD34 selection in the metastatic disease setting. Still, this study proves that this is a feasible method of treatment. Tumor depletion in the high-risk primary breast cancer patient with micrometastatic disease in the marrow may be the likely circumstance where CD34 selection can be shown to have an effect on disease-free and overall survival.
